Cost-Effectiveness of Afatinib and Erlotinib as Second-Line Treatments for Advanced Squamous Cell Carcinoma of The Lung in China
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.250
https://www.valueinhealthjournal.com/article/S1098-3015(17)30584-3/fulltext
Title :
Cost-Effectiveness of Afatinib and Erlotinib as Second-Line Treatments for Advanced Squamous Cell Carcinoma of The Lung in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30584-3&doi=10.1016/j.jval.2017.08.250
First page :
A442
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
228